Pre-exposure Prophylaxis
Active Resources: 33
Clinical Reference Tools
-
12/11/2018
Webinar Recordings
-
12/11/2017
-
6/4/2015 (reviewed: 10/12/2015)
-
4/30/2015 (reviewed: 10/12/2015)
Curricula
-
11/1/2017
Prevention & Testing Guidelines (PEP, PrEP, PWP)
-
10/1/2017
-
4/18/2016
-
12/11/2014
-
9/5/2014
-
5/14/2014
Online Training
-
8/23/2017
-
9/15/2016
Toolkits
-
6/30/2017 (reviewed: 11/14/2017)
-
10/30/2015
Slide Sets
-
4/28/2017
-
12/15/2015
-
5/19/2015
-
6/1/2014
Online and Self-Paced Learning
-
11/2/2016
Pocket Guides
-
10/17/2016
Reports
-
2/1/2016
-
9/1/2015
-
8/27/2015
-
6/25/2015
Fact Sheets
-
12/31/2015
Primary Care Guidelines
-
11/9/2015
-
10/29/2014
Charts, Tables & Posters
-
9/4/2015
Patient Information
-
8/7/2015
Coinfection Guidelines (Hep, TB, STIs)
-
6/5/2015
Videos
-
4/1/2015
-
2/4/2014
Web Links
-
3/1/2015
Archive Resources: 6
Slide Sets
-
1/15/2014
Webinar Recordings
-
1/9/2014
-
12/12/2012
Prevention & Testing Guidelines (PEP, PrEP, PWP)
-
8/10/2012
-
1/28/2011
Articles: 5
-
AETCs at the 2018 Ryan White Conference
The AETC Program will be well represented at the 2018 National Ryan White Conference on HIV Care & Treatment. Additionally, the AETC National Coordinating Resource Center will be exhibiting an array of AETC Program developed resources and promotional items at Booth #12 in...
-
U=U in PARTNER2 Study of MSM
PARTNER1, whose results were reported last year,(1) was one of the studies that supported current efforts to promote the growing scientific consensus supporting "Treatment as Prevention" (TasP) or Undetectable = Untransmittable (U=U).
PARTNER1 evaluated HIV...
-
HIV Meds Update: PrEP Uptake by Sex, Race, and Age
At the ASM Microbe meeting in June, researchers from Gilead Sciences presented data on use of TDF/FTC (Truvada) PrEP in the United States according to sex and race. They evaluated national pharmacy databases to identify prescriptions of TDF/FTC given for PrEP between January 2012 and September...
-
PrEP: Bone Density Improves after Stopping TDF/FTC
Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD) both in HIV-infected patients treated with TDF-containing ARV regimens and in HIV-uninfected persons who use it for PrEP. A substudy of the large iPrEx trial of TDF/FTC PrEP in MSM and transgender women...
-
Tissue Levels of TAF: Too Low for PrEP?
A pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue and in anogenital fluid samples after administration of oral tenofovir...
| Day | Title |
|---|---|
|
3/13 |
HIV Prevention: nPEP and PrEP
Event type: Webinars
|
|
3/18 |
|
|
3/27 |
HIV Prevention: PrEP for Adolescents
Event type: Webinars
|
|
5/1 |
HIV & Women: PrEP
Event type: Webinars
|